The cytokine cluster located on chromosome 5 has been shown by linkage studies to play a role in the genetic determination of circulating immunoglobulin E (IgE) levels in atopic subjects. In the study presented here, the reported chromosome 5 linkage has been investigated in two sets of subjects. The first consisted of a general population sample of 230 nuclear families (n= 1004) from Busselton, a small West Australian country town. The second group consisted of 124 unrelated atopic asthmatics and 59 unrelated non-atopic, non-asthmatic controls, all resident in the Oxfordshire Regional Health Authority area in the United Kingdom. A previously reported interleukin-4 (11-4) promoter polymorphism (-590 C-iT) was analysed in these populations by a newly designed method of specific PCR amplification and BsmFI restriction endonuclease digestion. In the Busselton population the polymorphism was shown to be weakly associated with specific IgE to house dust mite (Mann-Whitney-U test, p=0.013) and to wheeze (MWU test, p=0.029), but not with specific IgE to grass pollen, total serum IgE, bronchial hyperresponsiveness, eosinophil count, or asthma. In the Oxfordshire subjects there were no statistically significant associations with any measure of asthma or atopy. These data show that the -590 C-iT 11-4 promoter polymorphism is only weakly associated with certain measures of asthma and atopy in some subjects. It was specifically not associated with serum IgE concentration or asthma in either of the two groups in this study.
The response of the immune system to allergens is governed by a large range of factors, both environmental and genetic. There is ample evidence that environmental factors influence the development of allergic diseases such as asthma, eczema, and hay fever' (collectively known as atopy) and there is now evidence that genetic factors are important as well.`'-Asthma, eczema, and hay fever involve chronic inflammation of the airways, the skin, and the nasal mucous membranes. These three conditions may be seen alone, or together in the same patient. They lead to substantial losses in working hours and significant morbidity and mortality.
The IgE mediated mechanism which results in an inflammatory response is important in neutralising invading pathogens, typically extracellular parasites such as hookworm (Ancylostoma duodenale) or the blood fluke (Schistosoma mansonz).' In atopy, the same mechanism is triggered by ubiquitous allergens, such as the faeces of the house dust mite, cat and dog dander, and grass pollen.
The allergic response begins with the allergen being bound by specific IgE, the latter already being bound to the high affinity IgE receptor (FceRI) on mast cells and basophils. Cross linking of the immunoglobulin receptor complex on the cell surface leads to a signalling cascade involving phospholipase C and protein kinase C pathways. The cascade triggers an acute response in which histamine, prostaglandin D2, platelet activating factor, interleukin-4 (I1-4), and other cytokines are released from cytoplasmic granules. I1-4 activates the pre-T helper cells5 so that they become Th2 cells. 6 7 These cells then trigger isotype switching in B cells from IgG/IgM to IgE, subsequently enhancing the degranulation of mast cells by increasing the saturation of FceRI receptors with allergen/IgE complexes.
In the absence of continued allergen challenge, the inflammatory response is reduced to basal level by cytokines that switch Th2 cells to the Thl phenotype. These cytokines include interleukin-12, transforming growth factor beta, and interferon gamma.8 The heterogeneity of atopy has been explained by differing levels in cytokines between atopic and non-atopic subjects.9 '°However, it should be noted that at least one study has found no correlation between I1-4 expression and serum IgE levels in atopic subjects."
Genetic markers within and around 5q3 1-33 have been shown to be linked to total serum IgE concentration in the USA'2 and Holland.'3 1" They have provided strong evidence that there are one or more loci in 5q31-33 that are closely involved in raised serum IgE levels and bronchial hyperresponsiveness. The gene encoding interleukin-4 is within this region and is therefore a possible candidate for the reported genetic linkage.
An SSCP I1-4 marker had previously been linked to asthma,'5 when three different interleukins were analysed for promoter polymorphisms. This interleukin-4 promoter polymorphism was found to be present at high fre-quency in asthmatics (35/95 = 0.37). It was also associated with a raised serum IgE concentration. The polymorphism is a C to T change at position -590 counting from the first ATG codon."6 The polymorphism is upstream of all the previously described control elements of interleukin-47-" as shown in fig 1. It may nevertheless form part of a previously undescribed element, because it has been shown that regions as far upstream as -3000 are required for full wild type expression levels.2' Recently, Rosenwasser" has reported binding of nuclear factors to this region, and has shown enhanced activity for the variant promoter when placed in a luciferase reporter gene expression construct.
To assess the possible role of this I1-4 polymorphism in modulating the allergic response, 230 nuclear families were taken from a general Australian population who have been studied in detail for measures of asthma and atopy. To test further whether the polymorphism influences asthma, a set of children with asthma and a set of normal controls were taken from a UK population.
Methods

SUBJECTS
The first group was obtained from the town of Busselton, West Australia, and consisted of 1004 people from 230 nuclear families, as described previously.23 The second group consisted of 124 unrelated atopic asthmatics and 59 unrelated non-atopic, non-asthmatics all resident in the Oxfordshire Regional Health Authority area in the United Kingdom. Atopic, asthmatic probands under the age of 21 were identified through hospital outpatient clinics or through general practitioners' surgeries. The controls were normal sibs of probands from the same subject group but from different families.
CLINICAL PARAMETER MEASUREMENT
All subjects were asked to complete a questionnaire, based upon the American Thoracic Society questionnaire, but including questions on allergies and rhinitis. In both sets of subjects, "asthma" was a positive answer to the questions: "Have you ever had an attack of asthma?" and "If yes, has this happened on more than one occasion?". "Wheeze" was defined as a positive answer to the questions: "Has your chest ever sounded wheezy or whistling?" and "If yes, has this happened on more than one occasion?". In Oxfordshire, the asthma was also clinically diagnosed. Bronchial responsiveness to methacholine challenge was measured in the Busselton subjects only (maximum dose 12 ,umol) and the dose required to provoke a 20% fall in forced expiratory volume in one second (PD20) was calculated by linear interpolation. Subjects in whom a 20% fall was not achieved by the maximum dose of methacholine were assigned an arbitrary PD20 of 100. Bronchial hyperresponsiveness (BHR) was defined as PD20 less than or equal to 8 gmol of methacholine. '4 Atopy was defined as a positive skin test to house dust mite (Dermatophagoides pteronyssinus) or timothy grass (Phleum pratense) greater than 4 mm greater than a negative control. Total serum IgE and specific IgE responses to whole house dust mite and timothy grass were determined using the Pharmacia CAP system (Pharmacia Biotech, Uppsala, Sweden), which is a fluorescent enzyme immunoassay system (FEIA). This system gives equivalent values for IgE to the older radioallergosorbent test (RAST). The peripheral blood eosinophil count was counted automatically (Western Diagnostic Laboratories, Western Australia and Haematology Department, John Radcliffe Hospital, Oxford). There was no significant difference in polymorphism frequency between the Busselton and Oxfordshire non-asthmatic subjects (table 1). The Oxfordshire asthmatics had a 192 bp slightly higher frequency of 0.33 than the nonasthmatic, non-atopic controls, but this was lower than the previously reported value of 0.37 in white American asthmatics."5 to the clinical symptom of wheeze (p=0.029).
None of the traits analysed in the Oxfordshire subjects were significantly associated with the polymorphism. Table 3 shows the calculated relative risk of having asthma or wheeze in subjects with the -590 C-*T polymorphism. Only the relative risk for wheeze was significant in the Busselton population with a value of 1.33 and 95% confidence intervals of 1.03-1.72. There was no relationship of the polymorphism to asthma in either of the populations.
Discussion
These results show that the 11-4 promoter polymorphism is found at a population prevalence of 0.26-0.27 in the two study groups. The slightly increased frequency in the Oxfordshire asthmatics (0.33) is not significantly different from the non-asthmatic controls. The similar population prevalences of the promoter polymorphism between the Busselton and Oxford populations contrasts with the finding of statistically significant associations in the former and not the latter. This may be because of the lower levels of atopy and asthma in the Busselton subject group (table 1) showing an effect that is masked in the Oxfordshire group. It is also likely that although the two subject groups are genetically close, the disparate environments of the two groups could explain these differences.
Interleukin-4 is central to the allergic response and the findings of the present study differ from those of the previous report of the polymorphism. 15 Rosenwasser" has recently reported that this polymorphism is involved in regulating promoter activity in vitro, but the present study provides little evidence that the polymorphism is associated with asthma or atopy in vivo. However, other polymorphisms in interleukin-4 may be functionally important in the subjects studied. It seems increasingly possible that, although interleukin-4 is an ideal candidate gene for atopy and asthma, it is not responsible for the reported linkages to the chromosome 5q31-33 region.
